Intervention

JS111 capsules (AP-L1898)

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions2

Lead sponsors shown2

Clinical trials

2 shown

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLCNCT07714304 · 2026-07-13

NOT_YET_RECRUITING

JS111 in Patients With Advanced NSCLC Harboring EGFR MutationsNCT06940401 · 2025-04-30

ACTIVE_NOT_RECRUITING

Common conditions

NSCLC1 NSCLC Harboring EGFR Mutations1

Leading sponsors

Huan Zhou1 Suzhou Junjing BioSciences Co., Ltd.1

Trial status mix

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

Phase mix

NA1

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.